Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31385340 | 0.85 | MAOA (0.55) | MAOAMAOBSMN1; SMN2CHRM2ALDH1A1 | |
| SCHEMBL7749926 | 0.85 | MAOA (0.55) | MAOAMAOBSMN1; SMN2CHRM2ALDH1A1 | |
| SCHEMBL19214858 | 0.81 | CYP1A2 (0.46) | MAOAMAOBSMN1; SMN2CHRM2ALDH1A1 | |
| SCHEMBL18160751 | 0.81 | MEN1 (0.45) | MAOAMAOBSMN1; SMN2CHRM2ALDH1A1 | |
| SCHEMBL21790794 | 0.79 | MAOA (0.46) | MAOAMAOBSMN1; SMN2CHRM2ALDH1A1 | |
| SCHEMBL16741775 | 0.77 | MAOA (0.47) | MAOAMAOBSMN1; SMN2CHRM2ALDH1A1 | |
| SCHEMBL16225118 | 0.77 | MAOA (0.51) | MAOAMAOBSMN1; SMN2CHRM2HRH3 | |
| SCHEMBL21192306 | 0.76 | MAOA (0.46) | MAOAMAOBSMN1; SMN2CHRM2ALDH1A1 | |
| SCHEMBL18190229 | 0.76 | MAOA (0.46) | MAOAMAOBSMN1; SMN2CHRM2ALDH1A1 | |
| SCHEMBL18049905 | 0.76 | MAOA (0.53) | MAOAMAOBSMN1; SMN2CHRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | MAOA 2332/4885MAOB 1117/4885SMN1; SMN2 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.